The incidence of hepatitis E virus (HEV) infection has been steadily increasing across the countries of the European Union and European Economic Area (EU/EEA) with 21 081 cases reported in the EU/EEA over the last decade.
In this report, we provide an overview of the data reported by countries in the EU and EEA in 2023 to describe progress towards the 2025 interim targets for hepatitis elimination as outlined in the WHO European Region Action Plan 2022–2030.
ECDC is following reports from several European Union and European Economic Area (EU/EEA) countries of substantial increases in the detection of parvovirus B19 (B19V).
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
Hepatitis E is one of the most common causes of acute hepatitis in the EU/EEA but currently not notifiable at EU level. This presentation summarises ECDC's work on the topic and survey results on hepatitis E on 2005 to 2015 data.
The purpose of this study was to assess current testing, diagnosis, and surveillance for HEV in EU/EEA Member States, and to conduct a baseline assessment of available epidemiological data.
This report presents findings related to the hepatitis B and C continuum of care, policy on testing and treatment, and the impact of the COVID-19 pandemic on hepatitis services in the EU/EEA from the second data collection conducted in 2021.
Hepatitis E is an acute or chronic infection with the hepatitis E virus (HEV). In Europe, most of the infections are locally-acquired and asymptomatic.
Second update of a previous assessment on the ongoing transmission of hepatitis A virus infection mainly affecting men who have sex with men in EU/EEA countries.